Find Funding Opportunities

Request Information RFI) the Action Plan the Muscular Dystrophies Notice Number: NOT-NS-14-039 Key Dates Release Date: August 30, 2013   Response Date: December 20, 2013 Related Announcements None Issued National Institute Neurological Disorders Stroke NINDS) National Heart, Lung, Blood Institute NHLBI) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) Purpose NIH, together the Muscular Dystrophy Coordinating Committee MDCC), leading effort update Action Plan the Muscular Dystrophies, was released 2005.  help inform planning process, NIH the MDCC welcome comments the public regarding accomplishments since Plan’s approval, remaining opportunities, suggestions new research objectives. Background NIH’s mission to seek fundamental knowledge the nature behavior living systems the application that knowledge enhance health, lengthen life, reduce illness disability. National Institute Neurological Disorders Stroke NINDS), National Institute Arthritis Musculoskeletal Skin Diseases NIAMS), Eunice Kennedy Shriver National Institute Child Health Human Development NICHD), the National Heart, Lung, Blood Institute NHLBI) fund majority muscular dystrophy-related research NIH work together coordinate muscular dystrophy research activities across NIH.  muscular dystrophies a group hereditary, progressive degenerative disorders causing weakness the skeletal voluntary muscles.  are different forms muscular dystrophy, differ their age onset, severity, pattern muscles other body systems affected.  Among provisions, Muscular Dystrophy Community Assistance, Research, Education Amendments 2001 MD-CARE Act, Public Law 107-84) established MDCC prompted series activities leading the development the Action Plan the Muscular Dystrophies.  Action Plan, developed input an MDCC Scientific Working Group, includes research objectives five areas: Mechanisms Muscular Dystrophy, Diagnosis Screening Muscular Dystrophy, Therapy Muscular Dystrophy, Living Muscular Dystrophy, Research Infrastructure Needs Muscular Dystrophy.  Through individual collaborative activities researchers, clinicians, stakeholders in  muscular dystrophy community, driven, part, the Action Plan, have significant advances understanding disease mechanisms, development new diagnostic tools reduce diagnostic odyssey affected individuals their families, evolution drug discovery development partnerships have advanced candidate therapeutics, improvements the care quality life affected individuals.  While type muscular dystrophy distinctive, has required disease-appropriate activities, has benefited a shared focus the muscular dystrophy community.  this time, are new challenges gaps require assessment progress a re-focus current needs. Information Requested NIH the MDCC invite muscular dystrophy research, advocacy, family communities provide comments their perspective progress toward objectives the Action Plan, on remaining opportunities.  NIH also welcomes suggestions modifications the existing research objectives, research objectives are longer needed, new objectives should considered the updated Action Plan.  collected comments be reviewed considered the MDCC an MDCC Scientific Working Group develop updated Action Plan.  to Submit Response Responses this RFI must submitted electronically using web-based format at: http://www.ninds.nih.gov/funding/RFI-MuscularDystrophies.htm. Responses be accepted until December 20, 2013.  Responses this RFI voluntary.  Submitted information not considered confidential.  Any personal identifiers be removed responses compiled. request for information planning purposes only should be construed a solicitation as obligation the part the Federal Government. NIH does intend make any awards based responses this RFI to otherwise pay the preparation any information submitted for Government's of such information. NIH use information submitted response this RFI its discretion will provide comments any responder’s submission. However, responses the RFI be reflected future funding opportunity announcements. information provided be analyzed may appear reports. Respondents advised the Government under obligation acknowledge receipt the information received provide feedback respondents respect any information submitted.  proprietary, classified, confidential, sensitive information should included your response. Government reserves right use any non-proprietary technical information any resultant solicitation(s). Inquiries Please direct inquiries to: John D. Porter, Ph.D. Executive Secretary, Muscular Dystrophy Coordinating Committee National Institute Neurological Disorders Stroke Telephone: 301-496-5745 Email: mailto:porterjo@ninds.nih.gov nbsp;

Discontinuation PAR-12-097 Ancillary Studies PREDICT-HD U01)" Notice Number: NOT-NS-13-037 Key Dates Release Date: July 25, 2013 Effective Date:   August 15, 2013 Related Announcements PAR-12-097 Issued National Institute Neurological Disorders Stroke NINDS) Purpose Notice informs potential applicants NINDS discontinue PAR-12-097  "Ancillary Studies PREDICT-HD U01)". Applications not accepted NINDS this Funding Opportunity Announcement after August 14, 2013 Application Due Date. Inquiries Please direct inquiries to: Margaret Sutherland, Ph.D Program Director, National Institute Neurological Disorders Stroke 6001 Executive Blvd, Bethesda, MD 20892 Telephone: 301-496-5680 Email: sutherlandm@ninds.nih.gov nbsp;

Discontinuation Participation NINDS PA-11-196 Mentored Quantitative Research Development Award K25)" Notice Number: NOT-NS-13-031 Key Dates Release Date: July 18, 2013 Related Announcements PA-11-196 Issued National Institute Neurological Disorders Stroke NINDS) Purpose notice informs potential applicants NINDS discontinue participation PA-11-196 quot;Mentored Quantitative Research Development Award Parent K25)." New applications not accepted NINDS this award after September 7, 2013. Resubmitted A1) applications not accepted after 7, 2014. other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Stephen Korn, Ph.D. National Institute Neurological Disorders Stroke Office Training, Career Development, Workforce Diversity 6001 Executive Blvd, Room 2186 Bethesda, MD 20892 Telephone: 301) 496-4188 Email: korns@ninds.nih.gov nbsp;

Request Information RFI): Advancing Research Parkinson's Disease 2014 Notice Number: NOT-NS-13-035 Update: following update relating this announcement been issued: September 26, 2013 - Notice NOT-NS-13-042. Notice the Extension the Response Date. Key Dates Release Date: July 18, 2013 Response Due Date: September 30, 2013 Extended October 31, 2013 per NOT-NS-13-042) Issued National Institute Neurological Disorders Stroke NINDS) Purpose National Institute Neurological Disorders Stroke NINDS), part the National Institutes Health NIH), the primary federal agency responsible funding research Parkinson's Disease PD). January 6-7, 2014, NINDS sponsor public conference assess critical needs related opportunities advancing PD research treatment. purpose this time-sensitive Request Information RFI) to seek comprehensive perspective the most significant challenges highest priorities basic, translational clinical research PD. RFI intended gather information relevant conference planning should be construed a funding opportunity. Information Requested RFI intended solicit broad community perspective scientific opportunities outstanding needs research treatment PD. NINDS invites input stakeholders including not limited researchers academia industry, healthcare professionals, patient advocates advocacy organizations, scientific professional organizations, Federal agencies other interested members the public. Organizations encouraged submit single response reflects views the organization a whole. Responses be used inform 2014 NINDS PD conference. NINDS interested basic, translational clinical PD research, well interdisciplinary approaches span areas. Please provide perspectives the following topics: New and/or ongoing challenges opportunities PD research treatment breakthroughs. highest individual priority PD each the following: basic, translational clinical research; well the impact accomplishment stated priority areas have laboratory-based science, clinical trials, patient well-being public health. Specific elements needed address basic, translational clinical priorities to remove any related obstacles. Examples such elements might include are limited to: enhanced tools, technologies, research resources; novel combinations research team expertise collaboration; bioinformatics resources; infrastructure. to Submit Response ensure consideration, responses must received September 30, 2013 must submitted electronically using web-based format www.ninds.nih.gov/funding/RFI-PD.htm. web format provide confirmation response submission, respondents not receive individualized feedback. Responses this RFI voluntary may submitted anonymously. Please not include any personally identifiable other information you not wish make public. Proprietary, classified, confidential sensitive information should be included your response. Comments submitted be compiled discussion the upcoming January 2014 conference may appear related reports. Any personal identifiers names, e-mail addresses, etc.) be removed responses compiled. RFI for informational planning purposes only should be construed a solicitation as obligation the part the United States US) Government, NIH the NINDS provide support any ideas submitted response it. Please note the US Government, NIH NINDS not pay the preparation any information submitted, for use that information. Inquiries Please direct inquiries to: Beth-Anne Sieber, PhD Program Director, Neurodegeneration National Institute Neurological Disorders Stroke Email: sieberb@ninds.nih.gov

Notice Intent Publish Revised Funding Opportunity Announcement NeuroNEXT Clinical Trials U01) Notice Number: NOT-NS-13-036 Update: following update relating this announcement been issued: August 30, 2013 - Issuance PAR-13-343 NeuroNEXT Clinical Trials U01). Key Dates Release Date: July 16, 2013 Estimated Publication Date Announcement: September, 2013  First Estimated Application Due Date: December 2, 2013 Earliest Estimated Award Date: June, 2014 Earliest Estimated Start Date: July, 2014 Related Announcements PAR-11-343 NOT-NS-13-034 Issued National Institute Neurological Disorders Stroke NINDS) Purpose NINDS intends reissue PAR-11-343 solicit applications NeuroNEXT Clinical Trials U01). revised Funding Opportunity Announcement FOA) expected be published Fall 2013 an expected initial application due date December 2013. FOA utilize U01 activity code. Details the planned FOA provided below. Research Initiative Details Notice encourages investigators begin consider applying this revised FOA. revised FOA encourage applications biomarker validation trials exploratory clinical trials drugs, biologics, surgical therapies devices may contribute the justification and provide data required design subsequent trial further evaluate intervention. Applications drugs biologics should provide compelling scientific evidence the investigational agent proposed study reach/act upon designated target that mechanism action such it be benefit ameliorating specific aspect the disease. Applications devices propose early traditional feasibility studies. Diseases chosen study should based the NINDS' strategic plan clinical research interests.  APPLICATIONS NOT BEING SOLICITED THIS TIME. Inquiries Please direct inquiries to: D. Elizabeth McNeil, MD MSc National Institute Neurological Disorders & Stroke Telephone: 301-496-9135 Email: mcneilde@ninds.nih.gov  

Notice Support Clinician-Scientists Supported NINDS Mentored Career Development K08 K23 Awards Attend Workshop Notice Number: NOT-NS-13-028 Key Dates Release Date: July 16, 2013 Issued National Institute Neurological Disorders Stroke NINDS) Purpose year, NINDS the American Neurological Association ANA) sponsor workshop designed specifically clinician-scientists obtain Mentored Career Development Award K08 K23) NINDS. workshop also available clinician-scientists supported other mentored K awards, including K12 K99 awards. workshop organized run based the expectation participation have large, beneficial influence the success K awardees their pursuit a dual career outstanding clinicians independently funded research scientists. workshop been given annually over 10 years, evaluated updated annually has considered be very beneficial those have attended.  faculty this workshop includes senior NINDS staff, Chairs Neurology Departments, established clinician-scientists neurology clinician-scientists recently transitioned mentored K awards independent funding. workshop covers wide range topics, including grant writing, career development problem solving multiple issues pertinent this population. addition, workshop includes poster session significant opportunities attendees network among peers, leaders neurology research NINDS staff. NINDS/ANA workshop typically begins the Friday evening continues day the Saturday immediately preceding start the ANA annual meeting. NINDS K awardees invited attend workshop twice non-consecutive years) during 5 year K award period. is intended K awardees attend workshop during 1st 4th year the K award. However, is understood time conflicts arise, historically, K awardees attended during 2nd, 3rd and/or 5th year their awards. purpose this Notice to inform NINDS K awardees a change financial support provided their K awards, is intended facilitate attendance this workshop. Currently, mentored NINDS K awards include 50,000 per year research career development expenses. Effective June 1, 2013, new awards subsequent May, 2013 NINDS council, additional 1,000 per year be added the research cost budget, a total 51,000 per year. additional funding being provided the expectation K awardees use or of to attend NINDS-ANA sponsored workshop twice during first four years the K award. Starting K awards on after June 1, 2013, K awardees expected attend workshop twice, once during either 1st 2nd year the K award once during 3rd 4th year the K award not consecutive years). is highly recommended scholars attend during 1st 4th year, it understood that, due scheduling conflicts, timetable not always possible. Because much the emphasis the workshop preparation transition independent funding, should in process during 5th year, funds not provided attendance the workshop during 5th year the award. additional 5,000 over duration the award being provided specifically enable attendance the annual workshop. Consequently, K awardees have attended workshop twice during first 4 years their K award receive total 46,000 the year 5 research cost budget, will maintain research cost budget the K award an average 50,000 per year support research career development activities. Inquiries Please direct inquiries to: Stephen Korn, Ph.D. Director Office Training, Career Development Workforce Diversity National Institute Neurological Disorders Stroke NINDS) 6001 Executive Boulevard, Room 2153  Bethesda, Maryland 20892 Phone: 301- 496-4188 Email: korns@ninds.nih.gov Website: http://www.ninds.nih.gov/funding/areas/training_and_career_development/…

Notice Intent Publish Funding Opportunity Announcement the NINDS Morris K. Udall Centers Excellence Parkinson's Disease Research P50) Notice Number: NOT-NS-13-033 Key Dates Release Date: July 11, 2013 Estimated Publication Date Announcement: November, 2013  First Estimated Application Due Date: January, 2014  Earliest Estimated Award Date: July, 2014  Earliest Estimated Start Date: July, 2014  Issued National Institute Neurological Disorders Stroke NINDS) Purpose National Institute Neurological Disorders Stroke NINDS) continue Morris K. Udall Centers Excellence Parkinson's Disease Research program publishing Funding Opportunity Announcement FOA) new renewal applications. purpose this Notice to alert potential applicants to provide lead time the development responsive projects.  FOA utilize Specialized Center P50) activity code, will support spectrum basic, translational clinical research activities utilizing integrated, multidisciplinary approach a specific disease entity, Parkinson's Disease PD).   is anticipated this FOA be published autumn 2013 an expected application due date early winter 2014. Research Initiative Details NINDS intends solicit new renewal applications the Morris K. Udall Centers Excellence Parkinson’s Disease Research program, consortium specialized Centers work collaboratively well independently define causes and discover improved treatments this disease. Individual Centers establish unique, interdisciplinary programs optimize available expertise basic, translational clinical research required advance PD research. overall theme, proposed research projects integral cores each Center relate directly the etiology, pathogenesis treatment PD related parkinsonian disorders. considerable degree collaboration among investigators required achieve overarching objectives each Center. proposal must include least translational research project focusing the development therapeutics, diagnostics, clinical criteria will inform new approaches the treatment PD. Notably, Centers Excellence, Udall Centers serve regional national resources PD research. Successful applicants participate the network existing Udall Centers foster translation scientific findings novel treatments PD. Applicants request maximum annual direct costs 1,500,000. Full details be available the FOA. APPLICATIONS NOT BEING SOLICITED THIS TIME. Inquiries Please direct inquiries to: Beth-Anne Sieber, PhD Program Director, Neurodegeneration Cluster Division Extramural Research National Institute Neurological Disorders Stroke 6001 Executive Boulevard, Room 2223 Bethesda, MD 20892-9525 Telephone: 301) 496-5680 Email: sieberb@ninds.nih.gov

Discontinuation PAR-11-343 NeuroNEXT Clinical Trials U01)" Notice Number: NOT-NS-13-034 Update: following update relating this announcement been issued: July 16, 2013 - Notice NOT-NS-13-036. Notice Intent Publish Revised Funding Opportunity Announcement NeuroNEXT Clinical Trials U01). Key Dates Release Date: July 3, 2013 Related Announcements PAR-11-343 Issued National Institute Neurological Disorders Stroke NINDS) Purpose Notice informs potential applicants NINDS discontinue PAR-11-343 NeuroNEXT Clinical Trials U01). Applications not accepted NINDS this Funding Opportunity Announcement after August 3, 2013. Inquiries Please direct inquiries to: D. Elizabeth McNeil, MD, MSc National Institute Neurological Disorders Stroke Office Clinical Trials 6001 Executive Blvd, Room 2114 Bethesda, MD 20892 Telephone: 301) 496-4135 Email: mcneilde@ninds.nih.gov  

Notice Change Earliest Start Date Applications Submitted RFA-DA-14-002 Short-term Mentored Career Enhancement Awards the Basic Behavioral Social Sciences: Cross-Training the Intersection Animal Models Human Investigation K18)" Notice Number: NOT-DA-13-040 Key Dates Release Date: June 24, 2013 Related Announcements RFA-DA-14-002 Issued NIH Basic Behavioral amp; Social Science Opportunity Network OppNet) behalf its constituent organizations: National Cancer Institute NCI) National Eye Institute NEI) National Heart, Lung, Blood Institute NHLBI) National Human Genome Research Institute NHGRI) National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Allergy Infectious Diseases NIAID) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Biomedical Imaging Bioengineering NIBIB) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Deafness Other Communication Disorders NIDCD) National Institute Dental Craniofacial Research NIDCR) National Institute Diabetes Digestive Kidney Diseases NIDDK) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) National Institute General Medical Sciences NIGMS) National Institute Mental Health NIMH) National Institute Neurological Disorders Stroke NINDS) National Institute Nursing Research NINR) National Institute Minority Health Health Disparities NIMHD) National Library Medicine NLM) Fogarty International Center FIC) National Center Complementary Alternative Medicine NCCAM) National Center Advancing Translational Sciences NCATS) Division Program Coordination, Planning Strategic Initiatives, Office Research Infrastructure Programs ORIP) Office Behavioral Social Sciences Research OBSSR) Office Dietary Supplements ODS) Office Research Women’s Health ORWH) Purpose notice changes start date RFA-DA-14-002 quot;Short-term Mentored Career Enhancement Awards the Basic Behavioral Social Sciences:  Cross-Training the Intersection Animal Models Human Investigation K18)". Currently reads: Earliest Start Date December 2014 Modified read: Earliest Start Date September 2014 other aspects the FOA remain same. Inquiries Please direct inquiries to: Minda Lynch, PhD National Institute Drug Abuse NIDA) Telephone: 301-435-1322 Email: mlynch1@mail.nih.gov Melissa S. Gerald, Ph.D. Division Behavioral Social Research National Institute Aging NIA) Phone: 301-402-4156 Email: melissa.gerald@nih.gov

Notice Intent Publish Funding Opportunity Announcement NINDS Clinical Trial Methodology Course R25) Notice Number: NOT-NS-13-030 Key Dates Release Date: June 14, 2013 Estimated Publication Date Announcement: August 2013 First Estimated Application Due Date: October 2013  Earliest Estimated Award Date: March 2014  Earliest Estimated Start Date: 2014 Issued National Institute Neurological Disorders Stroke NINDS) Purpose National Institute Neurological Disorders Stroke NINDS) intends issue Funding Opportunity Announcement FOA) solicit applications the NINDS Clinical Research Methods Course. goal this initiative to enhance training new investigators the conduct high-quality clinical trials. Notice being provided allow potential applicants sufficient time develop meaningful collaborations responsive projects.  FOA expected be published summer 2013 an expected application due date Fall 2013. FOA utilize R25 activity code. Details the planned FOA provided below. Research Initiative Details NINDS Clinical Research Methods Clinical Neurological Disorders course use R25 grant mechanism support educational course faculty any clinical neuroscience subspecialty introduce to principles good clinical trial design exposing early career clinical scientists the full spectrum challenges clinical research. NINDS aims develop cadre well-trained researchers whose expertise foster better clinical study design thereby lead improved regimens therapy prevention neurological disorders. is anticipated this annual course yield group talented, dedicated clinical neuroscience researchers will consequently in position obtain funding their own high quality clinical research.  the program successful, is anticipated participant scholars return their organizations/institutions where will take prominent role advancing local clinical research priorities neurology.  achieve objective, NINDS requires high-impact program enhancing training future researchers is innovative that exceeds training experiences available those treating neurological disease.  important part the NINDS extramural clinical trials budget spent early phase trials phase 1, 2, pilot trials) that primary focus this grant on training early phase clinical trials. Specific performance goals the FOA are: develop scientific content, curriculum, format a comprehensive, hands-on educational program incorporating innovative methods teaching conducting clinical research taking advantage knowledge gained disciplines outside neurology, emphasis proof principle studies new therapeutic agents, validating biomarkers use early phase clinical trials. organize conduct educational program, including recruitment selection faculty participants.  conduct formal evaluation the program and, where relevant, incorporate results subsequent course offerings. maximize course impact making didactic material available online the additional benefit a wider audience. is expected the grant tasks be performed two phases.  Phase comprises development the education program; Phase II includes conducting iteration the course course evaluation. APPLICATIONS NOT BEING SOLICITED THIS TIME. Inquiries Please direct inquiries to: Robin Conwit, MD Program Director Office Clinical Research National Institute Neurological Disorders Stroke Telephone: 301) 496-9135 Fax: 301) 410-1080 Email: Robin.Conwit@nih.gov nbsp;